CCL3 and myeloid sarcoma: Deletion of the CCL3 gene in Tregs results in partial disease protection in the MS mouse model. Anti-CCL3 treatment inhibited MNC recruitment into the CNS. Tregs deficient in CCL3 production fail to prevent (51).